Category: skin disease
March 8, 2023 / Eur Urol
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective…
March 3, 2023 / J Invest Dermatol
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA.
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed…
February 27, 2023 / Transl Med Commun
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors.
Background: This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods: Patients with percutaneously accessible malignancies scheduled for…
November 11, 2022 / Sci Immunol
Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells.
September 16, 2022 / J Invest Dermatol
Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis Suppurativa.
June 2, 2022 / Cancer Discov
The spatial landscape of progression and immunoediting in primary melanoma at single cell resolution.
January 10, 2022 / Nat Commun
Single cell transcriptomic landscape of diabetic foot ulcers.
November 16, 2021 / Clin Cancer Res
A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma.
November 16, 2021 / Microbiome